Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

Muscle and Nerve

Volumn 33, Issue 4, 2006, Pages 575-580

  Hain, Berit ^a   Jordan, Karin ^a   Deschauer, Marcus ^a   Zierz, Stephan ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

B lymphocytes; Immunosuppression; MuSK antibodies; Myasthenia gravis; Rituximab

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; MUSCLE ANTIBODY; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; BULBAR PARALYSIS; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MYASTHENIA GRAVIS; NEUROPHYSIOLOGY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY FAILURE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; PLASMA EXCHANGE; PREDNISOLONE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 33645328823     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20479     Document Type: Article

References (30)

1. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535.
2. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
3. Charlton B, Schindhelm F, Farrell PC. Extracorporeal antibody removal effect on antibody kinetics. Trans Am Soc Artif Intern Organs 1985;31:711-715.
4. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
5. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004;77:196-197.
6. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004;103:4416-4423.
7. Goldfarb AR, Weimer LH, Brannagan TH III. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle Nerve 2005;31:510-515.
8. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
9. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-242.
10. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536-538.
11. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099-1102.
12. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444-448.
13. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway, new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002;25:4-16.
14. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
15. Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Muller-Hermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch 1997;430:355-364.
16. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-584.
17. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-1440.
18. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-489.
19. Plested CP, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002;59:1682-1688.
20. Rodgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 1987;67:82-88.
21. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
22. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82:1139-1146.
23. Seybold ME, Tsoukas C, Lindstrom J, Fong S, Vaughan J. Leukoplasmapheresis for myasthenia gravis. Acetylcholine receptor antibody production. Arch Neurol 1982;39:433-435.
24. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-293.
25. Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda T. Anti-CD20 antibody (rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 2005;84:548-550.
26. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99-106.
27. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
28. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143:674-677.
29. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-1063.
30. Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004;30:55-60.